Re-assembled botulinum neurotoxin inhibits CNS functions without systemic toxicity

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Botulinum neurotoxin type A (BoNT/A) is a potent synaptic inhibitor but its diffusion poses safety concerns.
• BoNT/A functions by cleaving SNAP25, disrupting neurotransmitter release.
• Existing BoNT/A formulations carry risks of off-target neuromuscular blockade.

Purpose of the Study:

• To evaluate the safety and efficacy of a re-assembled BoNT/A using protein-stapling technology.
• To assess the systemic toxicity of the re-assembled BoNT/A in an animal model.
• To determine the potential of re-assembled BoNT/A as a research tool and therapeutic agent.

Main Methods:

• Protein-stapling technology was used to re-assemble BoNT/A from two fragments.
• The re-assembled toxin was tested in central nervous system (CNS) assays.
• Systemic effects were evaluated in an animal model following intraperitoneal injection.

Main Results:

• The re-assembled BoNT/A demonstrated potent inhibition of CNS function at nanomolar concentrations.
• No systemic toxicity was observed even at high doses (200 ng/kg) after intraperitoneal administration.
• The re-assembled toxin effectively silenced synaptic transmission in CNS assays.

Conclusions:

• Re-assembled BoNT/A exhibits potent neuroinhibitory activity.
• The protein-stapling approach yields a BoNT/A variant with a significantly improved safety profile.
• This re-assembled toxin represents a promising, safer tool for neuroscience research and potential medical applications.